Evidence map›Paper›PMID 40347395›Full record

ArticleClinical and experimental medicine2025

The effect of continuous infusion chemotherapy through femoral artery catheterization on GP73, AFP-L3, and safety efficacy in liver cancer patients.

Qiong Yan, Xinguo Sun, Yubo Wang, Shijiao Duan, Bo Wang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical and experimental medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Qiong YanInterventional Catheterization Room, Affiliated Nanhua Hospital, University of South China, Hengyang, 421002, China.
Xinguo SunInterventional Catheterization Room, Affiliated Nanhua Hospital, University of South China, Hengyang, 421002, China.
Yubo WangProduction Department, Guhan Traditional Chinese Medicine Co., Ltd, Hengyang, 421000, China.
Shijiao DuanInterventional Catheterization Room, Affiliated Nanhua Hospital, University of South China, Hengyang, 421002, China.
Bo WangPhysical examination center, Affiliated Nanhua Hospital, University of South China, Hengyang, 421002, China. 17707340609@163.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This study examines the impact of continuous infusion chemotherapy via femoral artery catheterization on Golgi protein 73 (GP73) and alpha fetoprotein heterogeneity (AFP-L3) in liver cancer patients. A retrospective analysis was conducted on 108 liver cancer patients treated from January 2020 to December 2022, divided into two groups: transarterial chemoembolization (TACE) and continuous infusion regional arterial chemotherapy via femoral artery catheterization (CIFAC), with 54 patients in each group. Serum tumor markers, liver function, adverse reactions, quality of life, and 1-year survival rate were analyzed and compared between the two groups of patients. Prior to treatment, no significant differences were observed in tumor markers, liver function, and quality of life between groups (P > 0.05). After 60 and 90 days, the CIFAC group exhibited significantly lower levels of GP73, AFP, and AFP-L3 compared to TACE (P < 0.05). Additionally, CIFAC patients had lower levels of alanine aminotransferase (ALT), aspartate transaminase (AST), indocyanine green (ICG15) (P < 0.05), reduced adverse reactions (nausea, vomiting, etc.), and higher Karnofsky scores (P < 0.05). The one-year survival rate of the CIFAC group was significantly higher than that of the TACE group (P < 0.05). Continuous infusion chemotherapy through femoral artery catheterization can help reduce serum tumor marker levels, improve liver function, and reduce adverse reactions in liver cancer patients.

Indexed as

alpha-FetoproteinsAntineoplastic AgentsCarcinoma, HepatocellularLiver NeoplasmsMembrane ProteinsAdultAgedBiomarkers, TumorChemoembolization, TherapeuticFemaleFemoral ArteryHumansInfusions, Intra-ArterialMaleMiddle AgedQuality of LifeAFP protein, humanalpha-FetoproteinsAntineoplastic AgentsBiomarkers, TumorGOLM1 protein, humanMembrane ProteinsAdverse reactionsContinuous infusion chemotherapy via femoral artery catheterizationLiver cancerLiver functionSerum tumor markers

Identifiers

PMID40347395
PMCPMC12065681

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.